Oral inhibitor shows clinical activity in poor-prognosis AML

(Dana-Farber Cancer Institute) An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia -- a poor-prognosis group with few options -- report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.